Ionetix Corp has disclosed important stock transactions involving its director, Michael P. Tarnok. The recent filing reveals that Tarnok acquired 100,000 stock options and 15,000 restricted stock units (RSUs) on October 23, 2026. This move is significant as it underscores the company's strategy to incentivize key personnel in the competitive diagnostics industry.

The stock options have an exercise price of $3.00, with a vesting period of one year from the grant date, contingent upon Tarnok's continued service. The RSUs will vest on January 1 following the year of the grant, also subject to his ongoing service at Ionetix.

Background

Ionetix Corp, based in Lansing, Michigan, operates within the In Vitro & In Vivo Diagnostic Substances sector (SIC 2835). The company is classified as a smaller reporting company and is an emerging growth entity. It was previously known as JDEV Acquisition Corp until a name change on January 28, 2026. Ionetix has been active in filing various forms with the SEC, including recent filings on October 27, 2026, which include multiple Form 4 submissions.

What the Filing Says

The SEC filing indicates that Tarnok's transactions involved:

“100,000 stock options (Right to Buy) at an exercise price of $3.00.”

“15,000 Restricted Stock Units.”

These transactions reflect a clear commitment from the company to align the interests of its leadership with those of its shareholders.

Impact

The transactions may impact Ionetix's ability to attract and retain top talent in the diagnostics industry. By offering stock options and RSUs, the company is positioning itself competitively against other firms in the sector. The move could also set a precedent for how other smaller reporting companies structure their compensation packages to incentivize key personnel.

What's Next

The filing does not say what happens next.